<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30998900</article-id>
<article-id pub-id-type="pmc">6545120</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2019.03.014</article-id>
<article-id pub-id-type="manuscript">NIHMS1029764</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nussbacher</surname>
<given-names>Julia K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tabet</surname>
<given-names>Ricardos</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yeo</surname>
<given-names>Gene W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lagier-Tourenne</surname>
<given-names>Clotilde</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Cellular and Molecular Medicine, Institute for Genomic Medicine, UCSD Stem Cell Program, University of California, San Diego, La Jolla, CA, USA</aff>
<aff id="A2"><label>2</label>Department of Neurology, The Sean M. Healey and AMG Center for ALS at Mass General, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA</aff>
<aff id="A3"><label>3</label>Broad Institute of Harvard University and MIT, Cambridge, MA 02142, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence: <email>geneyeo@ucsd.edu</email> (G.W.Y.), <email>clagier-tourenne@mgh.harvard.edu</email> (C.L.-T.)</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P43">DECLARATION OF INTERESTS</p>
<p id="P44">G.W.Y. is co-founder, member of the Board of Directors, equity holder, and paid consultant for Locana and Eclipse BioInnovations. G.W.Y. is co-founder of Enzerna and ProteoNA. G.W.Y. is a paid consultant for Aquinnah Pharmaceuticals and Ionis Pharmaceuticals and scientific advisory board member to Ribometrix and the Allen Institute of Immunology. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The authors declare no other competing financial interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>17</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>102</volume>
<issue>2</issue>
<fpage>294</fpage>
<lpage>320</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2019.03.014-->
<abstract id="ABS1">
<p id="P1">RNA binding proteins are critical to the maintenance of the transcriptome via controlled regulation of RNA processing and transport. Alterations of these proteins impact multiple steps of the RNA life cycle resulting in various molecular phenotypes such as aberrant RNA splicing, transport, and stability. Disruption of RNA binding proteins and widespread RNA processing defects are increasingly recognized as critical determinants of neurological diseases. Here, we describe distinct mechanisms by which the homeostasis of RNA binding proteins is compromised in neurological disorders through their reduced expression level, increased propensity to aggregate or sequestration by abnormal RNAs. These mechanisms all converge toward altered neuronal function highlighting the susceptibility of neurons to deleterious changes in RNA expression and the central role of RNA binding proteins in preserving neuronal integrity. Emerging therapeutic approaches to mitigate or reverse alterations of RNA binding proteins in neurological diseases are discussed.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>